{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:07:52Z","timestamp":1793311672608,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003711","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["MOST 106-2113-M-038-002"],"award-info":[{"award-number":["MOST 106-2113-M-038-002"]}],"id":[{"id":"10.13039\/501100003711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ejmech.2018.03.006","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T12:13:39Z","timestamp":1520252019000},"page":"667-677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC"],"prefix":"10.1016","volume":"150","author":[{"given":"Ritu","family":"Ojha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Li","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chun","family":"HuangFu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Nepali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Jung","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Jou","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Yi","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiow-Lin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Ping","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.03.006_bib1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ejmech.2014.03.018","article-title":"Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids","volume":"77","author":"Nepali","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.006_bib2","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1021\/jm400179b","article-title":"Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-Hydroxy-3-methylglutaryl coenzyme a reductase for cancer treatment","volume":"56","author":"Chen","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.006_bib3","doi-asserted-by":"crossref","DOI":"10.2174\/1568026617666170707124126","article-title":"Multi-Targeted anticancer agents","author":"Zheng","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.006_bib4","first-page":"67","article-title":"A.B.,Multi-Targeted agents in cancer cell chemosensitization: what we learnt from curcumin thus far, recent pat","volume":"11","author":"Bordoloi","year":"2016","journal-title":"Anti. Drug. Discov."},{"key":"10.1016\/j.ejmech.2018.03.006_bib5","doi-asserted-by":"crossref","first-page":"14017","DOI":"10.18632\/oncotarget.14876","article-title":"Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma","volume":"8","author":"Mondello","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2018.03.006_bib6","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1073\/pnas.1613091114","article-title":"Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis","volume":"114","author":"Andrews","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2018.03.006_bib7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2174\/0929867321666141216125528","article-title":"Multi-kinase inhibitors","volume":"22","author":"Garuti","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.006_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11523-014-0331-z","article-title":"Treatment of advanced thyroid cancer: role of molecularly targeted therapies","volume":"10","author":"Covell","year":"2015","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.ejmech.2018.03.006_bib9","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1021\/jm200799p","article-title":"Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors","volume":"55","author":"Guerrant","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.006_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","article-title":"The role of histone deacetylases (HDACs) in human cancer","volume":"1","author":"Ropero","year":"2007","journal-title":"Mol. Oncol"},{"key":"10.1016\/j.ejmech.2018.03.006_bib11","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","article-title":"Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells","volume":"92","author":"Paul","year":"2000","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2018.03.006_bib12a","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1007\/s002800100322","article-title":"Histone deacetylases and transcriptional therapywith their inhibitors","volume":"48","author":"Pandolfi","year":"2001","journal-title":"Canc. Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.03.006_bib12b","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1021\/jm901453q","article-title":"Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer","volume":"53","author":"Cai","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.006_bib13","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","article-title":"Discovery and development of SAHA as an anticancer agent","volume":"26","author":"Marks","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2018.03.006_bib14","first-page":"22","article-title":"Romidepsin for the treatment of peripheral T-celllymphoma","volume":"6","author":"Barbarotta","year":"2015","journal-title":"J.\u00a0Adv. Pract. Oncol"},{"key":"10.1016\/j.ejmech.2018.03.006_bib15a","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/ijc.23243","article-title":"Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models ofprostate cancer","volume":"122","author":"Qian","year":"2008","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.ejmech.2018.03.006_bib15b","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","article-title":"Panobinostat for thetreatment of multiple myeloma","volume":"21","author":"Laubach","year":"2015","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ejmech.2018.03.006_bib16a","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/jm400390r","article-title":"Discovery of the first histone deacetylase 6\/8 dual inhibitors","volume":"56","author":"Olson","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.006_bib16b","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1021\/acs.jmedchem.5b01478","article-title":"Structure-based design and synthesis of novel inhibitors targeting HDAC8 from schistosoma mansoni for the treatment of schistosomiasis","volume":"59","author":"Heimburg","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.006_bib17a","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s12020-015-0706-7","article-title":"Theheat shock protein 90 inhibitor SNX5422 has a synergistic activity with histonedeacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells","volume":"51","author":"Kim","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.ejmech.2018.03.006_bib17b","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood-2008-03-143644","article-title":"HDAC6 inhibition enhances 17-AAG\u2013mediated abrogation of hsp90 chaperone function in human leukemia cells","volume":"112","author":"Rao","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2018.03.006_bib18","first-page":"8420","article-title":"Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyratesynergistically induces apoptosis in human leukemia cells","volume":"63","author":"Rahmani","year":"2003","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2018.03.006_bib19","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2004-09-3413","article-title":"Combination of the histone deacetylase inhibitor LBH589and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AMLcells with activating mutation of FLT-3","volume":"105","author":"George","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2018.03.006_bib19a","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/sj.bjc.6605066","article-title":"TargetingHSP90 for cancer therapy","volume":"100","author":"Mahalingam","year":"2009","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.ejmech.2018.03.006_bib19b","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2018.03.006_bib21a","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ejmech.2016.10.038","article-title":"Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide","volume":"124","author":"Jeong","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.006_bib21b","first-page":"11","article-title":"Characterization of a novelHsp90 inhibitor with an extended duration of action","author":"Zhang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2018.03.006_bib21c","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1200\/JCO.2005.00.612","article-title":"Phase I pharmacokinetic and pharmacodynamicstudy of 17-allylamino, 17-demethoxygeldanamycin in patients withadvanced malignancies","volume":"23","author":"Banerji","year":"2005","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2018.03.006_bib22a","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nature19807","article-title":"The epichaperome is an integrated chaperome network that facilitates tumour survival","volume":"538","author":"Rodina","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.03.006_bib22b","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1158\/1078-0432.CCR-15-3068","article-title":"A\u00a0novel HSP90 inhibitor-drug conjugate to SN38 is highly effective in small cell lung cancer","volume":"22","author":"Gaponova","year":"2016","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ejmech.2018.03.006_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-61779-295-3_3","article-title":"Hsp90 and client protein maturation","volume":"787","author":"Wayne","year":"2011","journal-title":"Meth. Mol. Biol."},{"key":"10.1016\/j.ejmech.2018.03.006_bib24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","article-title":"HSP90 and the chaperoning of cancer","volume":"5","author":"Whitesell","year":"2005","journal-title":"Nat. Rev. canc."},{"key":"10.1016\/j.ejmech.2018.03.006_bib25","doi-asserted-by":"crossref","first-page":"8324","DOI":"10.1073\/pnas.91.18.8324","article-title":"Inhibitionof heat shock protein HSP90-pp60v-src heteroprotein complex formation bybenzoquinone ansamycins: essential role for stress proteins in oncogenictransformation","volume":"91","author":"Whitesell","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2018.03.006_bib26","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1021\/jm300197a","article-title":"Synthesis and biological evaluationof 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylaseinhibitors with antitumor activity in\u00a0vivo","volume":"55","author":"Lai","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.006_bib27","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/cbic.201300201","article-title":"1-Arylsulfonyl-5-(N-hydroxyacrylamide) indolines histone deacetylase inhibitors are potent cytokine release suppressors","volume":"14","author":"Lee","year":"2013","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2018.03.006_bib28","doi-asserted-by":"crossref","first-page":"43645","DOI":"10.1371\/journal.pone.0043645","article-title":"Anticancer activity of MPT0E028, a novel potent histone deacetylaseinhibitor, in human colorectal cancer HCT116 cells in\u00a0vitro and in\u00a0vivo","volume":"7","author":"Huang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2018.03.006_bib29","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1021\/jm401899x","article-title":"Azaindolylsulfonamides,with a more selective inhibitory effect on histone deacetylase 6activity, exhibit antitumor activity in colorectal cancer HCT116 cells","volume":"57","author":"Lee","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.006_bib30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ejmech.2014.10.052","article-title":"1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines aspotent histone deacetylase inhibitors suppressing the growth of prostatecancer cells","volume":"89","author":"Liu","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.006_bib31","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1349-7006.2011.02191.x","article-title":"The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in\u00a0vitro and in\u00a0vivo in non-small cell lung cancer","volume":"103","author":"Graham","year":"2012","journal-title":"Canc. Sci."},{"key":"10.1016\/j.ejmech.2018.03.006_bib32","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/0008-5472.CAN-13-3263","article-title":"Ganetespib and HSP90: translating preclinical hypotheses into clinical promise","volume":"74","author":"Proia","year":"2014","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2018.03.006_bib33","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1200\/JCO.2014.59.7328","article-title":"Phase I\/II study of HSP90 inhibitor AUY922 and erlotinib for EGFR-mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors","volume":"33","author":"Johnson","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2018.03.006_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/798052","article-title":"Influence of Hsp90 and HDAC inhibition and tubulin acetylation on perinuclear protein aggregation in human retinal pigment epithelial cells","volume":"2011","author":"Ryh\u00e4nen","year":"2011","journal-title":"J.\u00a0Biomed. Biotechnol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418302411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418302411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T01:37:03Z","timestamp":1565314623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418302411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":42,"alternative-id":["S0223523418302411"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.03.006","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}